Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis
Esther Benamu, José G. Montoya
Current Opinion in Infectious Diseases (2016) Vol. 29, Iss. 4, pp. 319-329
Closed Access | Times Cited: 127

Showing 1-25 of 127 citing articles:

Beyond binding: antibody effector functions in infectious diseases
Lenette L. Lu, Todd J. Suscovich, Sarah M. Fortune, et al.
Nature reviews. Immunology (2017) Vol. 18, Iss. 1, pp. 46-61
Open Access | Times Cited: 687
International Consensus Guidance for Management of Myasthenia Gravis
Pushpa Narayanaswami, Donald B. Sanders, Gil I. Wolfe, et al.
Neurology (2020) Vol. 96, Iss. 3, pp. 114-122
Open Access | Times Cited: 470
Thrombotic Microangiopathy and the Kidney
Vicky Brocklebank, Katrina M. Wood, David Kavanagh
Clinical Journal of the American Society of Nephrology (2017) Vol. 13, Iss. 2, pp. 300-317
Open Access | Times Cited: 311
Complement in neurological disorders and emerging complement-targeted therapeutics
Marinos C. Dalakas, Harry Alexopoulos, Peter J. Spaeth
Nature Reviews Neurology (2020) Vol. 16, Iss. 11, pp. 601-617
Open Access | Times Cited: 261
Community-acquired bacterial meningitis
Diederik van de Beek, Matthijs C. Brouwer, Rodrigo Hasbun, et al.
Nature Reviews Disease Primers (2016) Vol. 2, Iss. 1
Open Access | Times Cited: 252
The complement system as a potential therapeutic target in rheumatic disease
Leendert A. Trouw, Matthew C. Pickering, Anna M. Blom
Nature Reviews Rheumatology (2017) Vol. 13, Iss. 9, pp. 538-547
Closed Access | Times Cited: 176
Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications
Dani A. C. Heesterbeek, Mathieu L. Angelier, R. A. Harrison, et al.
Journal of Innate Immunity (2018) Vol. 10, Iss. 5-6, pp. 455-464
Open Access | Times Cited: 154
Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations
Caroline Diorio, Kevin O. McNerney, Michele P. Lambert, et al.
Blood Advances (2020) Vol. 4, Iss. 23, pp. 6051-6063
Open Access | Times Cited: 130
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
Kioa L. Wijnsma, Caroline Duineveld, Jack F.M. Wetzels, et al.
Pediatric Nephrology (2018) Vol. 34, Iss. 11, pp. 2261-2277
Open Access | Times Cited: 89
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)
Annika Y. Claßen, Larissa Henze, Marie von Lilienfeld‐Toal, et al.
Annals of Hematology (2021) Vol. 100, Iss. 6, pp. 1603-1620
Open Access | Times Cited: 61
Novel Immunotherapies for Myasthenia Gravis
Sruthi Nair, Saiju Jacob
ImmunoTargets and Therapy (2023) Vol. Volume 12, pp. 25-45
Open Access | Times Cited: 39
Targeted Complement Treatments in Glomerulopathies: A Comprehensive Review
Micaela Gentile, Lucio Manenti
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 702-702
Open Access | Times Cited: 1
Atypical Hemolytic Uremic Syndrome: A Brief Review
Kuixing Zhang, Yuxin Lu, Kevin Harley, et al.
Hematology Reports (2017) Vol. 9, Iss. 2, pp. 7053-7053
Open Access | Times Cited: 66
Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy
Stephan Bohl, Florian Kuchenbauer, S. von Harsdorf, et al.
Biology of Blood and Marrow Transplantation (2017) Vol. 23, Iss. 12, pp. 2172-2177
Open Access | Times Cited: 65
Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins
Yue Li, Sarah Jacques, Hanmant Gaikwad, et al.
Nature Nanotechnology (2023) Vol. 19, Iss. 2, pp. 246-254
Closed Access | Times Cited: 22
A comprehensive review of the advances in neuromyelitis optica spectrum disorder
Pakeeran Siriratnam, Saif Huda, Helmut Butzkueven, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 12, pp. 103465-103465
Open Access | Times Cited: 22
Current Therapies in Kidney Transplant Rejection
Sami Alasfar, Lavanya Kodali, Carrie A. Schinstock
Journal of Clinical Medicine (2023) Vol. 12, Iss. 15, pp. 4927-4927
Open Access | Times Cited: 21
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea
Vicky Brocklebank, David Kavanagh
Clinical Kidney Journal (2017) Vol. 10, Iss. 5, pp. 600-624
Open Access | Times Cited: 52
Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome
Fádi Fakhouri, Chantal Loirat
Seminars in Hematology (2018) Vol. 55, Iss. 3, pp. 150-158
Closed Access | Times Cited: 52
Complications of Immunosuppression in Glomerular Disease
J. Ashley Jefferson
Clinical Journal of the American Society of Nephrology (2018) Vol. 13, Iss. 8, pp. 1264-1275
Open Access | Times Cited: 51
Coagulopathy in COVID-19
G. М. Galstyan
PULMONOLOGIYA (2020) Vol. 30, Iss. 5, pp. 645-657
Open Access | Times Cited: 45
Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future
Evgenia Gurevich, Daniel Landau
Pediatric Drugs (2023) Vol. 25, Iss. 2, pp. 193-202
Open Access | Times Cited: 15
Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity
Todor Tschongov, Swagata Konwar, Andreas Büsch, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Current and emerging treatment options for autoimmune hemolytic anemia
Wilma Barcellini, Bruno Fattizzo, Anna Zaninoni
Expert Review of Clinical Immunology (2018) Vol. 14, Iss. 10, pp. 857-872
Closed Access | Times Cited: 46
Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
Patrick R. Walsh, Sally Johnson
Pediatric Nephrology (2018) Vol. 34, Iss. 9, pp. 1485-1492
Open Access | Times Cited: 45
Page 1 - Next Page

Scroll to top